- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vivoryon Therapeutics NV (VVY)
Vivoryon Therapeutics NV stock price live, this page displays AS VVY stock exchange data. View the VVY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vivoryon Therapeutics NV real time stock price chart below.
What Is the Vivoryon Therapeutics NV Stock Price Today?
The Vivoryon Therapeutics NV stock price today is 1.43.
What Is the Stock Symbol for Vivoryon Therapeutics NV?
The stock symbol for Vivoryon Therapeutics NV is "VVY."
What Stock Exchange Does Vivoryon Therapeutics NV Trade On?
Vivoryon Therapeutics NV is listed and trades on the Amsterdam stock exchange.
Is Vivoryon Therapeutics NV a Good Stock to Buy?
Determining whether Vivoryon Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VVY quote. (ISIN: NL00150002Q7)
What Is the Vivoryon Therapeutics NV Stock Price Today?
The Vivoryon Therapeutics NV stock price today is 1.43.
What Is the Stock Symbol for Vivoryon Therapeutics NV?
The stock symbol for Vivoryon Therapeutics NV is "VVY."
What Stock Exchange Does Vivoryon Therapeutics NV Trade On?
Vivoryon Therapeutics NV is listed and trades on the Amsterdam stock exchange.
Is Vivoryon Therapeutics NV a Good Stock to Buy?
Determining whether Vivoryon Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VVY quote. (ISIN: NL00150002Q7)
Currency in EUR
1.43
-0.01(-0.70%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.43
1.46
52 wk Range
1.37
2.26
VVY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.431.46
52 wk Range
1.372.26
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VVY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.50
Upside
+424.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Vivoryon Therapeutics NV Company Profile
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Vivoryon Therapeutics NV Earnings Call Summary for Q2/2025
- Net loss reduced to $5.5M from $13.6M, with R&D expenses cut by €7.5M, focusing on cost-effective clinical developments
- Lead product Varglutemstat secured US patent until 2044; cash runway extended to January 2026 with €4.8M in reserves
- Stock price dropped 6.33% to $1.60 despite improved financials; analysts set $9.91 target price
- Phase 2b study for diabetic kidney disease planned, with top-line data expected within 24 months
- Company exploring additional applications in rare kidney diseases and pursuing financing and partnership opportunities
Last Updated: 2025-09-04, 10:02 a/m
Read Full TranscriptCompare VVY to Peers and Sector
Metrics to compare | VVY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVVYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | 6.8x | −0.5x | |
PEG Ratio | −0.06 | 0.07 | 0.00 | |
Price/Book | 13.3x | 2.5x | 2.6x | |
Price / LTM Sales | - | 1.4x | 3.3x | |
Upside (Analyst Target) | - | 38.6% | 45.8% | |
Fair Value Upside | Unlock | 10.1% | 6.4% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.50
(+424.48% Upside)
Earnings
Latest Release
Dec 04, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Vivoryon Therapeutics (VVY) Stock Price Today?
The Vivoryon Therapeutics stock price today is 1.43
What Stock Exchange Does Vivoryon Therapeutics Trade On?
Vivoryon Therapeutics is listed and trades on the Amsterdam Stock Exchange.
What Is the Stock Symbol for Vivoryon Therapeutics?
The stock symbol for Vivoryon Therapeutics is "VVY."
What Is the Vivoryon Therapeutics Market Cap?
As of today, Vivoryon Therapeutics market cap is 42.29M.
What Is Vivoryon Therapeutics's Earnings Per Share (TTM)?
The Vivoryon Therapeutics EPS (TTM) is -0.48.
When Is the Next Vivoryon Therapeutics Earnings Date?
Vivoryon Therapeutics will release its next earnings report on Apr 23, 2026.
From a Technical Analysis Perspective, Is VVY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Vivoryon Therapeutics Stock Split?
Vivoryon Therapeutics has split 1 times.
How Many Employees Does Vivoryon Therapeutics Have?
Vivoryon Therapeutics has 14 employees.
What is the current trading status of Vivoryon Therapeutics (VVY)?
As of Feb 08, 2026, Vivoryon Therapeutics (VVY) is trading at a price of 1.43, with a previous close of 1.44. The stock has fluctuated within a day range of 1.43 to 1.46, while its 52-week range spans from 1.37 to 2.26.
What Is Vivoryon Therapeutics (VVY) Price Target According to Analysts?
The average 12-month price target for Vivoryon Therapeutics is EUR7.50, with a high estimate of EUR7.5 and a low estimate of EUR7.5. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +424.48% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.